Company intelligence / Profile preview
Peptinov
Paris, Île-de-France, France
- Ownership
- Private
- Employees
- ~15
- Development stage
- Phase 1
01
Overview
Peptinov has developed an active immunotherapy approach targeting self-proteins such as IL‑6. Its lead product completed a successful Phase I trial in knee osteoarthritis patients, showing excellent tolerability, induction of anti–IL‑6 antibodies in over 90% of patients, and improvement in patient experience. The company continues clinical development for inflammatory osteoarthritis of the knee and prevention of relapses in rare diseases linked to excess IL‑6. Additional pipeline candidates target chronic pain, inflammation, and oncology.
- Therapeutic areas
- RheumatologyImmunologyOncologyRare DiseasesNeurology
- Modalities
- Active immunotherapyPeptide-based therapeutics
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Peptinov.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Peptinov.